Skip to main content
Top

25-04-2024 | Nitroimidazoles | Review

Recent Progress in Synthesis of 99mTc-labeled Complexes with Nitroimidazoles as SPECT Probes for Targeting Tumor Hypoxia

Authors: Anh Thu Nguyen, Hee-Kwon Kim

Published in: Nuclear Medicine and Molecular Imaging

Login to get access

Abstract

The majority of solid tumors have hypoxia, or low oxygen levels, which is one of the hallmarks of cancer. Hypoxia was found to relate to cancer metastases and resistance to therapies, therefore, detection of hypoxia plays an important role in the process of cancer prognosis and treatment. Single-photon emission computed tomography (SPECT) is a non-invasive imaging technique using gamma-emitting radiopharmaceuticals to visualize biological activities within the body. SPECT is also applied for the detection of tumor hypoxia with the development of hypoxia-targeting radiopharmaceuticals. Radiopharmaceuticals containing nitroimidazole moieties have received increasing attention due to their bio-reducible characteristics which make the radiopharmaceuticals accumulate in the hypoxia regions. This review summarizes the recent development of 99mTc-labeled radiopharmaceuticals bearing nitroimidazoles for SPECT imaging of tumor hypoxia including the synthetic methods and results of animal studies.
Literature
1.
go back to reference Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: An evolving paradigm. Trends Mol Med. 2007;13:183–91.PubMedCrossRef Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: An evolving paradigm. Trends Mol Med. 2007;13:183–91.PubMedCrossRef
3.
go back to reference Murakami E, Nakamori M, Nakatani K, Shibata T, Tainaka K. Intracerebral distribution of CAG repeat-binding small molecule visualized by whole-brain imaging. Bioconjug Chem. 2023;34:2187–93.PubMedCrossRef Murakami E, Nakamori M, Nakatani K, Shibata T, Tainaka K. Intracerebral distribution of CAG repeat-binding small molecule visualized by whole-brain imaging. Bioconjug Chem. 2023;34:2187–93.PubMedCrossRef
4.
go back to reference Kim NH, Huh Y, Kim D. Benzo[g]coumarin-benzothiazole hybrid: A fluorescent probe for the detection of amyloid-beta aggregates. Bull Korean Chem Soc. 2022;43:764–8.CrossRef Kim NH, Huh Y, Kim D. Benzo[g]coumarin-benzothiazole hybrid: A fluorescent probe for the detection of amyloid-beta aggregates. Bull Korean Chem Soc. 2022;43:764–8.CrossRef
5.
go back to reference Sarker A, Suh M, Choi Y, Park JY, Kwon S, Kim H, et al. [64Cu] Cu-Albumin clearance imaging to evaluate lymphatic efflux of cerebrospinal space fluid in mouse model. Nucl Med Mol Imaging. 2022;56:137–46.PubMedPubMedCentralCrossRef Sarker A, Suh M, Choi Y, Park JY, Kwon S, Kim H, et al. [64Cu] Cu-Albumin clearance imaging to evaluate lymphatic efflux of cerebrospinal space fluid in mouse model. Nucl Med Mol Imaging. 2022;56:137–46.PubMedPubMedCentralCrossRef
6.
go back to reference Liu C, Zheng X, Dai T, Wang H, Chen X, Chen B, et al. Reversibly photoswitching upconversion nanoparticles for super‐sensitive photoacoustic molecular imaging. Angew Chem Int Ed. 2022; e202116802. Liu C, Zheng X, Dai T, Wang H, Chen X, Chen B, et al. Reversibly photoswitching upconversion nanoparticles for super‐sensitive photoacoustic molecular imaging. Angew Chem Int Ed. 2022; e202116802.
7.
go back to reference Tan TH, Ismail R. Utility of lung perfusion SPECT/CT in detection of pulmonary thromboembolic disease: outcome analysis. Nucl Med Mol Imaging. 2023;57:1–8.PubMedCrossRef Tan TH, Ismail R. Utility of lung perfusion SPECT/CT in detection of pulmonary thromboembolic disease: outcome analysis. Nucl Med Mol Imaging. 2023;57:1–8.PubMedCrossRef
8.
go back to reference Luu TG, Kim HK. 18F-Radiolabeled translocator protein (TSPO) PET tracers: Recent development of TSPO radioligands and their application to PET study. Pharmaceutics. 2022;14:2545.PubMedPubMedCentralCrossRef Luu TG, Kim HK. 18F-Radiolabeled translocator protein (TSPO) PET tracers: Recent development of TSPO radioligands and their application to PET study. Pharmaceutics. 2022;14:2545.PubMedPubMedCentralCrossRef
9.
go back to reference Kim MH, Jung WJ, Jeong HJ, Lee K, Kil HS, Chung WS, et al. Off-target screening of amyloid-beta plaque targeting [18F]florapronol ([18F]FC119S) in postmortem Alzheimer’s disease tissues. Bull Korean Chem Soc. 2022;43:859–67.CrossRef Kim MH, Jung WJ, Jeong HJ, Lee K, Kil HS, Chung WS, et al. Off-target screening of amyloid-beta plaque targeting [18F]florapronol ([18F]FC119S) in postmortem Alzheimer’s disease tissues. Bull Korean Chem Soc. 2022;43:859–67.CrossRef
10.
go back to reference Tran VH, Park H, Park J, Kwon YD, Kang S, Jung JH, et al. Synthesis and evaluation of novel potent TSPO PET ligands with 2-phenylpyrazolo [1, 5-a] pyrimidin-3-yl acetamide. Bioorg Med Chem. 2019;27:4069–80.CrossRef Tran VH, Park H, Park J, Kwon YD, Kang S, Jung JH, et al. Synthesis and evaluation of novel potent TSPO PET ligands with 2-phenylpyrazolo [1, 5-a] pyrimidin-3-yl acetamide. Bioorg Med Chem. 2019;27:4069–80.CrossRef
11.
go back to reference Hemrom A, Arora G, Damle NA, Bal C. Comparative role of 18F-DOPA PET/CT and 131I-MIBG scintigraphy in neuroblastoma and application of curie and SIOPEN scoring systems in 18F-DOPA PET/CT. Nucl Med Mol Imaging. 2022;56:236–44.PubMedPubMedCentralCrossRef Hemrom A, Arora G, Damle NA, Bal C. Comparative role of 18F-DOPA PET/CT and 131I-MIBG scintigraphy in neuroblastoma and application of curie and SIOPEN scoring systems in 18F-DOPA PET/CT. Nucl Med Mol Imaging. 2022;56:236–44.PubMedPubMedCentralCrossRef
12.
go back to reference Nguyen AT, Kim HK. Recent advances of 68Ga-Labeled PET radiotracers with nitroimidazole in the diagnosis of hypoxia tumors. Int J Mol Sci. 2023;24:10552.PubMedPubMedCentralCrossRef Nguyen AT, Kim HK. Recent advances of 68Ga-Labeled PET radiotracers with nitroimidazole in the diagnosis of hypoxia tumors. Int J Mol Sci. 2023;24:10552.PubMedPubMedCentralCrossRef
13.
go back to reference Kwon YD, Kang S, Park H, Cheong IK, Chang KA, Lee SY. Novel potential pyrazolopyrimidine based translocator protein ligands for the evaluation of neuroinflammation with PET. Eur J Med Chem. 2018;159:292–306.PubMedCrossRef Kwon YD, Kang S, Park H, Cheong IK, Chang KA, Lee SY. Novel potential pyrazolopyrimidine based translocator protein ligands for the evaluation of neuroinflammation with PET. Eur J Med Chem. 2018;159:292–306.PubMedCrossRef
15.
go back to reference Kasten BB, Jiang K, Cole D, Jani A, Udayakumar N, Gillespie GY, et al. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models. Eur J Nucl Med Mol Imaging. 2020;47:1412–26.PubMedCrossRef Kasten BB, Jiang K, Cole D, Jani A, Udayakumar N, Gillespie GY, et al. Targeting MMP-14 for dual PET and fluorescence imaging of glioma in preclinical models. Eur J Nucl Med Mol Imaging. 2020;47:1412–26.PubMedCrossRef
17.
go back to reference Kwon YD, Lee JY, La MT, Lee SJ, Lee SH, Park JH, et al. Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties. Eur J Med Chem. 2020;189:112099.PubMedCrossRef Kwon YD, Lee JY, La MT, Lee SJ, Lee SH, Park JH, et al. Novel multifunctional 18F-labelled PET tracer with prostate-specific membrane antigen-targeting and hypoxia-sensitive moieties. Eur J Med Chem. 2020;189:112099.PubMedCrossRef
18.
go back to reference Kwon YD, Oh JM, La MT, Chung HJ, Lee SJ, Chun SK, et al. Synthesis and evaluation of multifunctional fluorescent inhibitors with synergistic interaction of prostate-specific membrane antigen and hypoxia for prostate cancer. Bioconjug Chem. 2019;30:90–100.PubMedCrossRef Kwon YD, Oh JM, La MT, Chung HJ, Lee SJ, Chun SK, et al. Synthesis and evaluation of multifunctional fluorescent inhibitors with synergistic interaction of prostate-specific membrane antigen and hypoxia for prostate cancer. Bioconjug Chem. 2019;30:90–100.PubMedCrossRef
19.
go back to reference Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, et al. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD. Theranostics. 2022;12:7180–90.PubMedPubMedCentralCrossRef Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, et al. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD. Theranostics. 2022;12:7180–90.PubMedPubMedCentralCrossRef
20.
go back to reference Son H, Jang K, Lee H, Kim SE, Kang KW, Lee H. Use of molecular imaging in clinical drug development: a systematic review. Nucl Med Mol Imaging. 2019;53:208–15.PubMedPubMedCentralCrossRef Son H, Jang K, Lee H, Kim SE, Kang KW, Lee H. Use of molecular imaging in clinical drug development: a systematic review. Nucl Med Mol Imaging. 2019;53:208–15.PubMedPubMedCentralCrossRef
22.
go back to reference Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591–607.PubMedCrossRef Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov. 2008;7:591–607.PubMedCrossRef
23.
go back to reference Saraste A, Nekolla SG, Schwaiger M. Cardiovascular molecular imaging: An overview. Cardiovasc Res. 2009;83:643–52.PubMedCrossRef Saraste A, Nekolla SG, Schwaiger M. Cardiovascular molecular imaging: An overview. Cardiovasc Res. 2009;83:643–52.PubMedCrossRef
24.
go back to reference Strafella AP, Bohnen NI, Perlmutter JS, et al. Molecular imaging to track Parkinson’s disease and atypical parkinsonisms: New imaging frontiers. Mov Disord. 2017;32:181–92.PubMedCrossRef Strafella AP, Bohnen NI, Perlmutter JS, et al. Molecular imaging to track Parkinson’s disease and atypical parkinsonisms: New imaging frontiers. Mov Disord. 2017;32:181–92.PubMedCrossRef
25.
go back to reference Wu W, Yu F, Zhang P, et al. 68Ga-DOTA-NT-20.3 Neurotensin receptor 1 PET imaging as a surrogate for neuroendocrine differentiation of prostate cancer. J Nucl Med. 2022;63:1394–400. Wu W, Yu F, Zhang P, et al. 68Ga-DOTA-NT-20.3 Neurotensin receptor 1 PET imaging as a surrogate for neuroendocrine differentiation of prostate cancer. J Nucl Med. 2022;63:1394–400.
26.
go back to reference Wang G, Li L, Zhu M, et al. A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:3126–36.PubMedCrossRef Wang G, Li L, Zhu M, et al. A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:3126–36.PubMedCrossRef
27.
go back to reference Pauwels E, Celen S, Baete K, et al. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients. Eur J Nucl Med Mol Imaging. 2023;50:1134–45.PubMedCrossRef Pauwels E, Celen S, Baete K, et al. [18F] MFBG PET imaging: biodistribution, pharmacokinetics, and comparison with [123I] MIBG in neural crest tumour patients. Eur J Nucl Med Mol Imaging. 2023;50:1134–45.PubMedCrossRef
28.
go back to reference Al Badarin FJ, Malhotra S. Diagnosis and prognosis of coronary artery disease with SPECT and PET. Curr Cardiol Rep. 2019;21:57.PubMedCrossRef Al Badarin FJ, Malhotra S. Diagnosis and prognosis of coronary artery disease with SPECT and PET. Curr Cardiol Rep. 2019;21:57.PubMedCrossRef
29.
go back to reference Zhong X, Yan J, Ding X, Su C, Xu Y, Yang M. Recent advances in bioorthogonal click chemistry for enhanced PET and SPECT radiochemistry. Bioconjug Chem. 2023;34:457–76.PubMedCrossRef Zhong X, Yan J, Ding X, Su C, Xu Y, Yang M. Recent advances in bioorthogonal click chemistry for enhanced PET and SPECT radiochemistry. Bioconjug Chem. 2023;34:457–76.PubMedCrossRef
30.
go back to reference Bui TT, Kim HK. Recent advances in photo-mediated radiofluorination. Chem Asian J. 2021;16:2155–67.PubMedCrossRef Bui TT, Kim HK. Recent advances in photo-mediated radiofluorination. Chem Asian J. 2021;16:2155–67.PubMedCrossRef
31.
go back to reference Luu TG, Kim HK. Recent progress on radiofluorination using metals: Strategies for generation of C-18F bonds. Org Chem Front. 2023;13:5746–81.CrossRef Luu TG, Kim HK. Recent progress on radiofluorination using metals: Strategies for generation of C-18F bonds. Org Chem Front. 2023;13:5746–81.CrossRef
32.
go back to reference Kwon YD, Byun Y, Kim HK. 18F-labelled BODIPY dye as a dual imaging agent: Radiofluorination and applications in PET and optical imaging. Nucl Med Biol. 2021;93:22–36.PubMedCrossRef Kwon YD, Byun Y, Kim HK. 18F-labelled BODIPY dye as a dual imaging agent: Radiofluorination and applications in PET and optical imaging. Nucl Med Biol. 2021;93:22–36.PubMedCrossRef
33.
go back to reference Israel O, Pellet O, Biassoni L, et al. Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019;46:1990–2012.PubMedPubMedCentralCrossRef Israel O, Pellet O, Biassoni L, et al. Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019;46:1990–2012.PubMedPubMedCentralCrossRef
35.
go back to reference Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007;37:34–47.PubMedCrossRef Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med. 2007;37:34–47.PubMedCrossRef
36.
go back to reference Israel O, Pellet O, Biassoni L, De Palma D, Estrada-Lobato E, Gnanasegaran G, Kuwert T, et al. Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019;46:1990–2012.PubMedPubMedCentralCrossRef Israel O, Pellet O, Biassoni L, De Palma D, Estrada-Lobato E, Gnanasegaran G, Kuwert T, et al. Two decades of SPECT/CT - the coming of age of a technology: An updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019;46:1990–2012.PubMedPubMedCentralCrossRef
37.
go back to reference Papagiannopoulou D. Technetium-99m radiochemistry for pharmaceutical applications. J Labelled Comp Radiopharm. 2017;60:502–20.PubMedCrossRef Papagiannopoulou D. Technetium-99m radiochemistry for pharmaceutical applications. J Labelled Comp Radiopharm. 2017;60:502–20.PubMedCrossRef
38.
go back to reference EmamiNejad A, Najafgholian S, Rostami A, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21:62.CrossRef EmamiNejad A, Najafgholian S, Rostami A, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21:62.CrossRef
39.
go back to reference Hayashi Y, Yokota A, Harada H, Huang G. Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. Cancer Sci. 2019;110:1510–7.PubMedPubMedCentralCrossRef Hayashi Y, Yokota A, Harada H, Huang G. Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. Cancer Sci. 2019;110:1510–7.PubMedPubMedCentralCrossRef
40.
go back to reference Farina AR, Cappabianca L, Sebastiano M. et al. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. J Exp Clin Cancer Res. 2020;39:110. Farina AR, Cappabianca L, Sebastiano M. et al. Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer. J Exp Clin Cancer Res. 2020;39:110.
42.
go back to reference Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21:1516–54.PubMedPubMedCentralCrossRef Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21:1516–54.PubMedPubMedCentralCrossRef
43.
go back to reference Mittal S, Mallia MB. Molecular imaging of tumor hypoxia: Evolution of nitroimidazole radiopharmaceuticals and insights for future development. Bioorg Chem. 2023;139:106687.PubMedCrossRef Mittal S, Mallia MB. Molecular imaging of tumor hypoxia: Evolution of nitroimidazole radiopharmaceuticals and insights for future development. Bioorg Chem. 2023;139:106687.PubMedCrossRef
44.
go back to reference Kwon YD, Oh JM, Chun S, Kim HK. Synthesis and evaluation of multivalent nitroimidazole-based near-infrared fluorescent agents for neuroblastoma and colon cancer imaging. Bioorg Chem. 2021;113:104990.PubMedCrossRef Kwon YD, Oh JM, Chun S, Kim HK. Synthesis and evaluation of multivalent nitroimidazole-based near-infrared fluorescent agents for neuroblastoma and colon cancer imaging. Bioorg Chem. 2021;113:104990.PubMedCrossRef
45.
go back to reference Yang X, Wang F, Zhu H, Yang Z, Chu T. Synthesis and bioevaluation of novel [18F]FDG-conjugated 2-nitroimidazole derivatives for tumor hypoxia imaging. Mol Pharm. 2019;16:2118–28.PubMedCrossRef Yang X, Wang F, Zhu H, Yang Z, Chu T. Synthesis and bioevaluation of novel [18F]FDG-conjugated 2-nitroimidazole derivatives for tumor hypoxia imaging. Mol Pharm. 2019;16:2118–28.PubMedCrossRef
46.
go back to reference Lu J, Zhang C, Yang X, Yao XJ, Zhang Q, Sun XC. Synthesis and preliminary evaluation of a novel 18F-labeled 2-nitroimidazole derivative for hypoxia imaging. Front Oncol. 2021;10:1–9.CrossRef Lu J, Zhang C, Yang X, Yao XJ, Zhang Q, Sun XC. Synthesis and preliminary evaluation of a novel 18F-labeled 2-nitroimidazole derivative for hypoxia imaging. Front Oncol. 2021;10:1–9.CrossRef
47.
go back to reference Giglio J, Dematteis S, Fernández S, Cerecetto H, Rey A. Synthesis and evaluation of a new 99mTc(I)-tricarbonyl complex bearing the 5-nitroimidazol-1-yl moiety as potential hypoxia imaging agent. J Labelled Comp Radiopharm. 2014;57:403–9.PubMedCrossRef Giglio J, Dematteis S, Fernández S, Cerecetto H, Rey A. Synthesis and evaluation of a new 99mTc(I)-tricarbonyl complex bearing the 5-nitroimidazol-1-yl moiety as potential hypoxia imaging agent. J Labelled Comp Radiopharm. 2014;57:403–9.PubMedCrossRef
48.
go back to reference Wang J, Zheng X, Wu W, Yang W, Liu Y. Synthesis and preliminary biological evaluation of 99mTc(CO)3-labeled pegylated 2-nitroimidazoles. J Radioanal Nucl Chem. 2014;300:1013–20.CrossRef Wang J, Zheng X, Wu W, Yang W, Liu Y. Synthesis and preliminary biological evaluation of 99mTc(CO)3-labeled pegylated 2-nitroimidazoles. J Radioanal Nucl Chem. 2014;300:1013–20.CrossRef
49.
go back to reference Alberto R, Schibli R, Egli A, Schubiger AP. A novel organometallic aqua complex of technetium for the labeling of biomolecules: Synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc. 1998;120:7987–8.CrossRef Alberto R, Schibli R, Egli A, Schubiger AP. A novel organometallic aqua complex of technetium for the labeling of biomolecules: Synthesis of [99mTc(OH2)3(CO)3]+ from [99mTcO4]- in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc. 1998;120:7987–8.CrossRef
50.
go back to reference Alberto R, Schibli R, Waibel R, Abram U, Schubiger AP. Basic aqueous chemistry of [M(OH2)3(CO)3]+ (M=Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev. 1999;190–192:901–19.CrossRef Alberto R, Schibli R, Waibel R, Abram U, Schubiger AP. Basic aqueous chemistry of [M(OH2)3(CO)3]+ (M=Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev. 1999;190–192:901–19.CrossRef
51.
go back to reference Mallia MB, Subramanian S, Mathur A, Sarma HD, Banerjee S. A study on nitroimidazole-99mTc(CO)3 complexes as hypoxia marker: some observations towards possible improvement in in vivo efficacy. Nucl Med Biol. 2014;41:600–10.PubMedCrossRef Mallia MB, Subramanian S, Mathur A, Sarma HD, Banerjee S. A study on nitroimidazole-99mTc(CO)3 complexes as hypoxia marker: some observations towards possible improvement in in vivo efficacy. Nucl Med Biol. 2014;41:600–10.PubMedCrossRef
52.
go back to reference Mallia MB, Subramanian S, Mathur A, Sarma HD, Venkatesh M, Banerjee S. Synthesis and evaluation of 2-, 4- and 5-substituted nitroimidazole-iminodiacetic acid-99mTc(CO)3 complexes to target hypoxic tumors. J Label Compd Radiopharm. 2010;53:535–42.CrossRef Mallia MB, Subramanian S, Mathur A, Sarma HD, Venkatesh M, Banerjee S. Synthesis and evaluation of 2-, 4- and 5-substituted nitroimidazole-iminodiacetic acid-99mTc(CO)3 complexes to target hypoxic tumors. J Label Compd Radiopharm. 2010;53:535–42.CrossRef
53.
go back to reference Sun W, Chu T. In vivo click reaction between Tc-99m-labeled azadibenzocyclooctyne-MAMA and 2-nitroimidazole-azide for tumor hypoxia targeting. Bioorg Med Chem Lett. 2015;25:4453–6.PubMedCrossRef Sun W, Chu T. In vivo click reaction between Tc-99m-labeled azadibenzocyclooctyne-MAMA and 2-nitroimidazole-azide for tumor hypoxia targeting. Bioorg Med Chem Lett. 2015;25:4453–6.PubMedCrossRef
54.
go back to reference Mallia MB, Mittal S, Sarma HD, Banerjee S. Modulation of in vivo distribution through chelator: Synthesis and evaluation of a 2-nitroimidazole-dipicolylamine-99mTc(CO)3 complex for detecting tumor hypoxia. Bioorg Med Chem Lett. 2016;26:46–50.PubMedCrossRef Mallia MB, Mittal S, Sarma HD, Banerjee S. Modulation of in vivo distribution through chelator: Synthesis and evaluation of a 2-nitroimidazole-dipicolylamine-99mTc(CO)3 complex for detecting tumor hypoxia. Bioorg Med Chem Lett. 2016;26:46–50.PubMedCrossRef
55.
go back to reference Bhadwal M, Mallia MB, Sarma HD, Banerjee S. Neutral 99mTc(CO)3 complexes of “clicked” nitroimidazoles for the detection of tumor hypoxia. J Radioanal Nucl Chem. 2016;307:69–77.CrossRef Bhadwal M, Mallia MB, Sarma HD, Banerjee S. Neutral 99mTc(CO)3 complexes of “clicked” nitroimidazoles for the detection of tumor hypoxia. J Radioanal Nucl Chem. 2016;307:69–77.CrossRef
56.
go back to reference Zhang Q, Zhang Q, Guan Y, Liu S, Chen Q, Li X. Synthesis and biological evaluation of a new nitroimidazole-99mTc-complex for imaging of hypoxia in mice model. Med Sci Monit. 2016;22:3778–91.PubMedPubMedCentralCrossRef Zhang Q, Zhang Q, Guan Y, Liu S, Chen Q, Li X. Synthesis and biological evaluation of a new nitroimidazole-99mTc-complex for imaging of hypoxia in mice model. Med Sci Monit. 2016;22:3778–91.PubMedPubMedCentralCrossRef
57.
go back to reference Vats K, Mallia MB, Mathur A, Sarma HD, Banerjee S. ‘4+ 1’Mixed ligand strategy for the preparation of 99mTc-radiopharmaceuticals for hypoxia detecting applications. ChemistrySelect. 2017;2:2910–6.CrossRef Vats K, Mallia MB, Mathur A, Sarma HD, Banerjee S. ‘4+ 1’Mixed ligand strategy for the preparation of 99mTc-radiopharmaceuticals for hypoxia detecting applications. ChemistrySelect. 2017;2:2910–6.CrossRef
58.
go back to reference Rizvi SFA, Zhang H, Mehmood S, Sanad M. Synthesis of 99mTc-labeled 2-Mercaptobenzimidazole as a novel radiotracer to diagnose tumor hypoxia. Transl Oncol. 2020;13:100854.PubMedPubMedCentralCrossRef Rizvi SFA, Zhang H, Mehmood S, Sanad M. Synthesis of 99mTc-labeled 2-Mercaptobenzimidazole as a novel radiotracer to diagnose tumor hypoxia. Transl Oncol. 2020;13:100854.PubMedPubMedCentralCrossRef
59.
go back to reference Ruan Q, Gan Q, Zhang X, Fang S, Zhang J. Preparation and bioevaluation of novel 99mTc-labeled complexes with a 2-nitroimidazole HYNIC derivative for imaging tumor hypoxia. Pharmaceuticals. 2021;14:158.PubMedPubMedCentralCrossRef Ruan Q, Gan Q, Zhang X, Fang S, Zhang J. Preparation and bioevaluation of novel 99mTc-labeled complexes with a 2-nitroimidazole HYNIC derivative for imaging tumor hypoxia. Pharmaceuticals. 2021;14:158.PubMedPubMedCentralCrossRef
60.
go back to reference Su H, Chu T. Synthesis and bioevaluation of the cyclopentadienyl tricarbonyl technetium-99m 2-nitroimidazole derivatives for tumor hypoxia imaging. Bioorg Med Chem Lett. 2022;60:128583.PubMedCrossRef Su H, Chu T. Synthesis and bioevaluation of the cyclopentadienyl tricarbonyl technetium-99m 2-nitroimidazole derivatives for tumor hypoxia imaging. Bioorg Med Chem Lett. 2022;60:128583.PubMedCrossRef
61.
go back to reference Wang F, Fan D, Qian J, Zhang Z, Zhu J, Chen J. Preparation and biodistribution of technetium-99m-labeled bis-Misonidazole (MISO) as an imaging agent for tumour hypoxia. Med Chem. 2015;11:649–55.PubMedCrossRef Wang F, Fan D, Qian J, Zhang Z, Zhu J, Chen J. Preparation and biodistribution of technetium-99m-labeled bis-Misonidazole (MISO) as an imaging agent for tumour hypoxia. Med Chem. 2015;11:649–55.PubMedCrossRef
62.
go back to reference Li S, Chu T. Improving tumor/muscle and tumor/blood ratios of 99mTc-labeled nitroimidazole propylene amine oxime (PnAO) complexes with ethylene glycol linkers. Bioorg Med Chem Lett. 2023;82:129154.PubMedCrossRef Li S, Chu T. Improving tumor/muscle and tumor/blood ratios of 99mTc-labeled nitroimidazole propylene amine oxime (PnAO) complexes with ethylene glycol linkers. Bioorg Med Chem Lett. 2023;82:129154.PubMedCrossRef
63.
go back to reference Huang H, Zhou H, Li Z, Wang X, Chu T. Effect of a second nitroimidazole redox centre on the accumulation of a hypoxia marker: synthesis and in vitro evaluation of 99mTc-labeled bisnitroimidazole propylene amine oxime complexes. Bioorg Med Chem Lett. 2012;22:172–7.PubMedCrossRef Huang H, Zhou H, Li Z, Wang X, Chu T. Effect of a second nitroimidazole redox centre on the accumulation of a hypoxia marker: synthesis and in vitro evaluation of 99mTc-labeled bisnitroimidazole propylene amine oxime complexes. Bioorg Med Chem Lett. 2012;22:172–7.PubMedCrossRef
64.
go back to reference Lin X, Fang S, Teng Y, Zhang J. Preparation and biological evaluation of a technetium-99m labeled 4-nitroimidazole derivative for imaging tumor hypoxia. J Radioanal Nucl Chem. 2017;313:39–45.CrossRef Lin X, Fang S, Teng Y, Zhang J. Preparation and biological evaluation of a technetium-99m labeled 4-nitroimidazole derivative for imaging tumor hypoxia. J Radioanal Nucl Chem. 2017;313:39–45.CrossRef
65.
go back to reference Hay MP, Wilson WR, Moselen JW, Palmer BD, Denny WA. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J Med Chem. 1994;37:381–91.PubMedCrossRef Hay MP, Wilson WR, Moselen JW, Palmer BD, Denny WA. Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J Med Chem. 1994;37:381–91.PubMedCrossRef
66.
go back to reference Russell CD, Crittenden RC, Cash AG. Determination of net ionic charge on Tc-99m DTPA and Tc-99m EDTA by a column ion-exchange method. J Nucl Med. 1980;21:354–60.PubMed Russell CD, Crittenden RC, Cash AG. Determination of net ionic charge on Tc-99m DTPA and Tc-99m EDTA by a column ion-exchange method. J Nucl Med. 1980;21:354–60.PubMed
67.
go back to reference Lin X, Ruan Q, Lin L, Zhang X, Duan X, Teng Y, Zhang J. Biological evaluation and SPECT imaging of tumor hypoxia using a novel technetium-99m labeled tracer with 2-nitroimidazole moiety. J Radioanal Nucl Chem. 2018;317:1463–8.CrossRef Lin X, Ruan Q, Lin L, Zhang X, Duan X, Teng Y, Zhang J. Biological evaluation and SPECT imaging of tumor hypoxia using a novel technetium-99m labeled tracer with 2-nitroimidazole moiety. J Radioanal Nucl Chem. 2018;317:1463–8.CrossRef
68.
go back to reference Huellner MW, Strobel K. Clinical applications of SPECT/CT in imaging the extremities. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S50–8.PubMedCrossRef Huellner MW, Strobel K. Clinical applications of SPECT/CT in imaging the extremities. Eur J Nucl Med Mol Imaging. 2014;41(Suppl 1):S50–8.PubMedCrossRef
69.
go back to reference Sergieva S, Mangaldgiev R, Dimcheva M, Nedev K, Zahariev Z, Robev B. SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with recurrent prostate cancer. Nucl Med Rev Cent East Eur. 2021;24:70–81.PubMedCrossRef Sergieva S, Mangaldgiev R, Dimcheva M, Nedev K, Zahariev Z, Robev B. SPECT-CT Imaging with [99mTc]PSMA-T4 in patients with recurrent prostate cancer. Nucl Med Rev Cent East Eur. 2021;24:70–81.PubMedCrossRef
70.
go back to reference Mariani G, Bruselli L, Kuwert T, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging. 2010;37:1959–85.PubMedCrossRef Mariani G, Bruselli L, Kuwert T, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging. 2010;37:1959–85.PubMedCrossRef
71.
go back to reference Ćwikła JB, Roslan M, Skoneczna I, et al. Initial experience of clinical use of [99mTc]Tc-PSMA-T4 in patients with prostate cancer. A Pilot Study Pharmaceuticals. 2021;14:1107.PubMedCrossRef Ćwikła JB, Roslan M, Skoneczna I, et al. Initial experience of clinical use of [99mTc]Tc-PSMA-T4 in patients with prostate cancer. A Pilot Study Pharmaceuticals. 2021;14:1107.PubMedCrossRef
72.
go back to reference Urbán S, Meyer C, Dahlbom M, et al. Radiation dosimetry of 99mTc-PSMA I&S: A single-center prospective study. J Nucl Med. 2021;62:1075–81.PubMedCrossRef Urbán S, Meyer C, Dahlbom M, et al. Radiation dosimetry of 99mTc-PSMA I&S: A single-center prospective study. J Nucl Med. 2021;62:1075–81.PubMedCrossRef
73.
go back to reference Werner P, Neumann C, Eiber M, Wester HJ, Schottelius M. [99mTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020;10(1):45.PubMedPubMedCentralCrossRef Werner P, Neumann C, Eiber M, Wester HJ, Schottelius M. [99mTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center. EJNMMI Res. 2020;10(1):45.PubMedPubMedCentralCrossRef
Metadata
Title
Recent Progress in Synthesis of 99mTc-labeled Complexes with Nitroimidazoles as SPECT Probes for Targeting Tumor Hypoxia
Authors
Anh Thu Nguyen
Hee-Kwon Kim
Publication date
25-04-2024
Publisher
Springer Nature Singapore
Keyword
Nitroimidazoles
Published in
Nuclear Medicine and Molecular Imaging
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-024-00860-7